PD61-02 PREOPERATIVE PSMA PET/CT AS A PREDICTOR OF BIOCHEMICAL PERSISTENCE AND EARLY BIOCHEMICAL RECURRENCE

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy V (PD61)1 Sep 2021PD61-02 PREOPERATIVE PSMA PET/CT AS A PREDICTOR OF BIOCHEMICAL PERSISTENCE AND EARLY RECURRENCE Diederik Baas, Melline Schilham, Joost de Baaij, Eric Vrijhof, Robert Hoekstra, Rick Hermsen, Somford, and Jean-Paul van Basten BaasDiederik Baas More articles by this author , SchilhamMelline Schilham BaaijJoost Baaij VrijhofEric Vrijhof HoekstraRobert Hoekstra HermsenRick Hermsen SomfordDiederik Somford BastenJean-Paul View All Author Informationhttps://doi.org/10.1097/JU.0000000000002098.02AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: This study aims evaluate the predictive value suspected lymph nodes (LN) metastases on prostate-specific-membrane-antigen (PSMA) for biochemical persistence (BCP) early recurrence (BCR) following radical prostatectomy (RP) with extended pelvic node dissection (ePLND). METHODS: RP patients between September 1st, 2016 October 2020 were evaluated. Men intermediate or high-risk PCa preoperative 68Ga/18F-PSMA subsequent ePLND included. Performance was determined a per patient level. BCP defined as serum PSA level ≥0.1 ng/mL 6-20 weeks RP. Early BCR detectable >0.2 ≤12 months follow-up. Patients grouped PSMA- PSMA+ depending their LN status subdivided according histological (pN) ePLND. RESULTS: From 1058 consecutive patients, 213 met inclusion criteria. Median number resected 20 (IQR 15-26). versus results are presented in Table 1. Sensitivity, specificity, PPV, NPV accuracy detection metastatic LNs 29%, 83%, 33%, 80% 71% respectively. observed 26 211 (12%) 23 110 (21%). The incidence pN is illustrated Figure No correction made other risk factors. PSMA+/pN1 had significantly increased compared PSMA-/pN1 (p=0.004; p <0.001). CONCLUSIONS: should not be avoided men pre-operative negative PET/CT, 20% do N1 disease. positive confirmed pN1 disease those PET/CT. Source Funding: None © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1066-e1066 Advertisement Copyright & Permissions© Inc.MetricsAuthor Information Expand Loading ...